Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept 50 mg Once-weekly in Japanese RA Patients
NCT00418717Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Dec 2007
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoint: Disease Activity Score Using 28-joint Count and Erythrocyte Sedimentation Rate at 12 weeks. Started Feb 2007; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00418717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418717.